pelareorep
pelareorep: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| ONCOLYTICS BIOTECH INC (ONCY) | Phase 2 |
Clinical Trials (1)
An Open-Label, Randomized, Multicentre, Phase 2 Study of FOLFIRI + Bevacizumab + Pelareorep vs. FOLFIRI + Bevacizumab for the Second-Line Treatment of Metastatic, RAS-mutated, Microsatellite-Stable (MSS) Colorectal Cancer
FDA Decisions
FDA_MeetingDiscuss plans for a single-arm pivotal study for pelareorep and a checkpoint inhibitor in squamous cell anal carcinoma (SCAC).(ONCY)
Frequently asked questions
Who is developing pelareorep?
pelareorep is being developed by ONCOLYTICS BIOTECH INC.
How many clinical trials involve pelareorep?
BioSniper tracks 1 clinical trial involving pelareorep.
What is pelareorep's latest FDA decision?
The most recent tracked FDA decision for pelareorep is FDA_Meeting for Discuss plans for a single-arm pivotal study for pelareorep and a checkpoint inhibitor in squamous cell anal carcinoma (SCAC)..
Get deeper analysis on pelareorep
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis